A1 Refereed original research article in a scientific journal

A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo – A substudy for IBIS I Breast Cancer Prevention Trial



Subtitle: A substudy for IBIS I Breast Cancer Prevention Trial

Authors: Palva T, Ranta H, Koivisto AM, Pylkkänen L, Cuzick J, Holli K

Publisher: ELSEVIER SCI LTD

Publication year: 2013

Journal: European Journal of Cancer

Journal name in source: EUROPEAN JOURNAL OF CANCER

Journal acronym: EUR J CANCER

Number in series: 1

Volume: 49

Issue: 1

First page : 45

Last page: 51

Number of pages: 7

ISSN: 0959-8049

DOI: https://doi.org/10.1016/j.ejca.2012.06.015


Abstract
Conclusions: The discontinuation rate in the TAM group was high, and the discontinuations also occurred early. Even though there were significantly more non-serious gynaecological events during the TAM treatment, routine gynaecological follow-up cannot be recommended. (C) 2012 Elsevier Ltd. All rights reserved.



Last updated on 2024-26-11 at 21:27